Why to invest in SCHOTT Pharma

Global market leader in a highly attractive and protected industry

Global market leader in a highly attractive and protected industry

Pure player in injectables benefiting from healthcare megatrends

Pure player in injectables benefiting from healthcare megatrends

Strong shareholder value – high profitability and strong financials

Strong shareholder value – high profitability and strong financials

Pioneers and innovators shaping the industry since 1923

Pioneers and innovators shaping the industry since 1923

A long-term strategy with the right backing

A long-term strategy with the right backing

OUR EQUITY STORY

"

Leveraging our global position and trusted partnerships, SCHOTT Pharma is well-positioned to pursue exciting opportunities in the growing market for injectables and biologics. Our strong-margin, high-value solutions, such as prefillable syringes and ready-to-use solutions, enable us to meet the increasing demand to safely store and deliver the next generation of drugs.

 

Andreas Reisse, CEO SCHOTT Pharma

Andreas Reisse

SCHOTT Pharma in numbers (FY 2024)

m €
Revenues
m €
EBITDA
m €
Free cash flow
bn
Units produced p.a.
Patents

Annual Report 2023/2024 (Online)


Annual Report

Latest publications

Half-yearly financial report 2024/2025
Thursday, May 15, 2025 | Quarterly reports
Half-year report H1 2025
Presentation H1 2025
Thursday, May 15, 2025 | Presentations
Presentation H1 2025
Financial Factsheet Q2 2025
Thursday, May 15, 2025 | Factsheet
Financial Factsheet Q2 2025
f ALL PUBLICATIONS

Financial events

May 21 - 22, 2025
Berenberg European Conference
May 27 - 28, 2025
Deutsche Bank European Champio...
June 17, 2025
Oddo BHF Forum
ALL EVENTS

Get in touch

Please reach out to Investor Relations of SCHOTT Pharma.

Tobias Erfurth

Head of Investor Relations

Jasko Terzic, CFA

Senior Manager Investor Relations

If you are a journalist, please contact our Corporate Communications team.